Researchers launch two cancer trials with Exelixis' 'cabo'

Exelixis CEO Michael Morrissey.

Researchers at Memorial Sloan Kettering Cancer Center and Massachusetts General Hospital have launched separate trials using Exelixis Inc.'s experimental cancer-fighting drug cabozantinib. South San Francisco-based Exelixis (NASDAQ: EXEL) said Thursday that Dr.Naiyer Rizvi, a lung cancer specialist at Memorial Sloan-Kettering Cancer Center in New York, is working on a Phase II trial in non-small cell lung cancer patients. Also, Anuj Mahindra of Massachusetts General Hospital in Boston, is conducting a pilot Phase I trial in patients with relapsed or refractory multiple myeloma.